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1. Introduction 
Parkinson disease (PD) is caused by several pathogenic mutations in genes such as alpha-
synuclein (SNCA; MIM#163890), Leucine-rich repeat kinase 2 (LRRK2; MIM#609007), 
PARKIN (parkin; MIM#602544), PTEN-induced kinase 1 (PINK1; MIM#608309), and DJ-1 
(MIM#602533) (Farrer, 2006). The alpha-synuclein protein is also a major component of 
Lewy bodies (LB), the pathologic substrate that is observed in PD patients at autopsy 
(Spillantini et al., 1997). LB are generally localized to the mid-brain in patients with PD, 
however a widespread distribution of LB, including cortical regions, is seen in dementia 
with Lewy bodies (DLB) (Braak et al., 2003, McKeith et al., 2005). The observation of SNCA 
multiplications co-segregating with PD and dementia in families led to the hypothesis that 
over-expression of the alpha-synuclein protein is an important mechanism of disease. 
Herein, we place the gene dosage effect of SNCA in PD in perspective and describe the 
recent molecular insights underlying them.  
2. SNCA triplication and duplication in hereditary PD 
PD is the second most frequent neurodegenerative disorder following Alzheimer disease in 
the elderly. The main symptoms of PD are tremor, bradykinesia, and gait disturbance. PD 
genetics is categorized into two groups; one is sporadic PD and the other is familial PD. 
Familial PD has two forms; autosomal dominant heredity (ADPD) and autosomal recessive 
heredity (ARPD). ADPD has been observed to be caused by mutations in SNCA and LRRK2. 
ARPD is caused by homozygous or compound heterozygous mutations in PARKIN, PINK1, 
and DJ-1(Farrer, 2006). This review will focus on SNCA which is located on chromosome 
4q21-22 and encodes the 140 amino acid alpha-synuclein protein. SNCA has three point 
mutations; c.88G>C (Ala30Pro), c.188G>A (Glu46Lys) and c.209G>A (Ala53Thr) (Kruger et 
al., 1998, Zarranz et al., 2004), but they are very rare.  
SNCA duplications and triplications have also been identified as a genetic cause of ADPD. 
Duplication has two SNCA copies on one allele (50% dose increase) and triplication has 
three, 100 percent dose increase (Figure 1). Rarely, compound heterozygote forms (two 
duplication alleles) are seen as SNCA triplication events (Ikeuchi et al., 2008). These 
multiplications generate higher SNCA expression of mRNA and protein, the so called gene 
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dosage effect. Increasing the levels of protein appears to influence the clinical manifestations 
of PD patients. A subtle increase in alpha-synuclein expression may increase the risk of 
developing typical sporadic PD, whereas higher expression may cause severe forms of 
Parkinsonism similar to DLB. Pathologically, the burden of LB correlates with a PD or DLB 
clinical diagnosis, and it is still unclear whether PD and DLB are a continuum within the 
disease spectrum.  
 
 
Fig. 1. A model for gene dosage of deletion, duplication and triplication 
Singleton et al. first reported SNCA gene triplication within a large family with PD and 
dementia family (the Iowa kindred) (Singleton et al., 2003). The family members had been 
followed both clinically and pathologically by Mayo Clinic doctors for 100 years (Muenter et 
al., 1998, Gwinn-Hardy et al., 2000). The pattern of inheritance is autosomal dominant. The 
patients show a severe clinical course, early age at onset, complicating with dementia, or 
Parkinsonism. The pathological features are similar to DLB; (1) widespread LB pathology in 
the brain, (2) neuronal loss in the CA2/3, and (3) neuronal loss in the substantia nigra 
(Muenter et al., 1998). SNCA triplication was confirmed with quantitative PCR and FISH 
methodology. The size of the triplication region was over 2.0Mb. The expression values of 
messenger RNA and protein in peripheral blood and brain were twice the amount that is 
present in control subjects as predicted (Miller et al., 2004). Apart from the Iowan family, a 
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Swedish-American family was also reported as a SNCA triplication family and the patients 
had DLB-type prognosis and pathological findings. Their expression level of messenger 
RNA and protein of alpha-synuclein was also double the dosage of normal subjects in 
frontal cortex (Farrer et al., 2004).  
These findings provided two novel insights regarding the underlying mechanisms of PD; (1) 
over-expression of alpha-synuclein may cause a more severe form of Parkinsonism such as 
DLB and (2) the gene dosage of alpha-synuclein may directly correlate with the clinical 
features of PD. Furthermore, these findings give us hints into the development of potential 
therapeutic avenues of treatment for PD by decreasing the expression of alpha-synuclein. 
The suppression of alpha-synuclein by siRNA approaches has proven successful in 
decreasing the levels of LB pathology in animal models (Lewis et al., 2008, McCormack et 
al., 2010).  
After the detection of SNCA locus triplication, SNCA duplications were also reported in two 
families from France and Italy (Chartier-Harlin et al., 2004, Ibanez et al., 2004). Chartier-
Harlin et al detected one duplication family among nine ADPD. Ibanez et al detected two 
families with SNCA duplication among 119 ADPD by 250K Affymetrix microarray and 
semi-quantitative PCR method(Ibanez et al., 2004). The symptoms of the patients with 
SNCA duplication are milder than that of SNCA triplication, younger age at onset and have 
a good efficacy for levodopa therapy, similar to sporadic PD.  
Following these findings, we started screening for SNCA multiplications within 216 ADPD 
and 271 sporadic PD patients originating from Japan (Nishioka et al., 2006, Nishioka et al., 
2009). We found six ADPD families and one sporadic case with SNCA duplication. 
Haplotype analysis showed these seven patients are derived from four common founders. 
Interestingly, the clinical manifestations of these patients were quite diverse such as 
sporadic PD, DLB-type and also many elderly asymptomatic carriers. The estimated 
penetrance ratio is about 30-40%. One patient presented with a severe clinical course with 
no efficacy for levodopa therapy. He progressed to Hoehn and Yahr stage V in a few years 
and at autopsy demonstrated features similar to DLB (Obi et al., 2008).  
In addition, we also detected five asymptomatic carriers over 65 years old. We therefore 
focused our work on the reasons why the asymptomatic carriers at later ages do not present 
any clinical features of parkinsonism. We started to assess Brain MRI, PET study with [18F]-
labeled 2-fluoro-2-deoxy-D-glucose (FDG) and [11C]-labeled 2β-carbomethoxy-3β-(4-
flurophenyl)-tropane (CFT), polysomnography, and Sniffin’ sticks to explore the differences 
between the patients and the asymptomatic carriers with SNCA duplication. Against our 
expectation, the assessments for asymptomatic carriers did not show any abnormal results 
in our studies, with similar results as those obtained for normal individuals (Nishioka et al., 
2009). It is an area of intense research why the asymptomatic carriers do not develop 
Parkinsonism at these late ages and its resolution will be a key in the puzzle regarding the 
late-onset of PD.  
Apart from our cases, other teams have reported two families from Japan with SNCA 
duplication (Ikeuchi et al., 2008, Uchiyama et al., 2008). Interestingly, one family has both 
heterozygote and homozygote duplication (producing a pseudo-triplication) (Ikeuchi et al., 
2008). The clinical features of the individual with the SNCA homozygote duplication 
showed severe Parkinsonism similar to that of a triplication carrier. These findings also 
confirm the gene dosage effect within the same family. Earlier studies had reported that the 
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Swedish family named the “Lister family complex” has both SNCA duplication and 
triplication patients within different branches of the pedigree suggesting a primary 
duplication event followed later by another resulting in the triplication (Fuchs et al., 2007). 
In this family also the patient with SNCA triplication presented with more severe symptoms 
than the patients with duplication. Recently one small pedigree with SNCA triplication was 
detected in Japan (Sekine et al., 2010).  
The breakpoint of SNCA multiplication is different in each family. The largest multiplication 
about 4.9Mb is detected within a French family. The smallest one about 0.2 Mb is in a 
Japanese family (Nishioka et al., 2009). The size and gene make-up of each multiplication 
region does not seem to influence the clinical presentation of the carrier. The single common 
determining factor that appears between all patients with SNCA multiplication is the 
presence of the entire SNCA gene. To conclude, it is clear that SNCA multiplication alone is 
sufficient to result in the parkinsonian phenotype.  
2.1 Sporadic PD and SNCA duplication 
In 2007, Ahn et al reported two sporadic patients with SNCA duplication from a screen of 
906 PD patients (Ahn et al., 2008). The age at onset was 65 and 50 years old for the two 
patients. Their clinical course was similar to typical sporadic PD without severe progression 
or cognitive decline. The estimated penetrance ratio was 33.3% among the Korean patients. 
Our studies have also detected one sporadic patient with SNCA duplication and this means 
that the low penetrance SNCA duplications may give the appearance of sporadic disease.  
2.2 The frequency of SNCA multiplications in PD 
The prevalence of SNCA multiplications is relatively low (table 1). Bruggemann et al 
reported one sporadic case among 403 PD cases from Germany (1/403=0.25%) 
(Brueggemann et al., 2008). Troiano et al reported one sporadic cases among 101 young 
onset PD cases from French (1/101=1%) (Troiano et al., 2008). Nuytemans et al reported one 
duplication patient with dementia among 219 sporadic PD cases from Belgium (Nuytemans 
et al., 2009). Sironi et al reported one duplication patient with dementia among 144 PD cases 
from Italy (1/144=0.7%) (Sironi et al., 2009). Furthermore some reports did not detect SNCA 
duplication; 0/50 and 0/290 (Hope et al., 2004, Xiromerisiou et al., 2007). To conclude, 
SNCA multiplication is not a common cause of sporadic or hereditary PD.  
2.3 SNCA multiplications in multiple system atrophy 
Multiple system atrophy (MSA) is characterized by specific clinical features such as 
Parkinsonism, autonomic dysfunction, poor response to levodopa therapy, and cerebellar 
ataxia (Wenning et al., 2004). Glial cytoplasmic inclusions (GCIs) are the pathologic 
hallmark of the disease. As alpha-synuclein is a major protein component of GCIs, MSA is 
categorized within the group of neurodegenerative disorders classified as the alpha-
synucleinopathies. Interestingly common variation at the SNCA locus has been associated 
with MSA risk (Scholz et al., 2009, Ross et al., 2010). Two studies did not identify any SNCA 
multiplications in a combined total of 258 MSA patients (Lincoln et al., 2007, Ahn et al., 
2008). Although the number of assessed samples may be small, these findings suggest that 
SNCA dosage is not a common cause of MSA. It is speculated that PD or DLB may be cause 
by lysosomal dysfunction, however, MSA may be caused by the oligodendrocytic changes 
in myelin basic protein (Wenning et al., 2008).  
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 Country The number
of pedigrees
The number of 
screening samples
Frequency 
(%) 
 Average 
ot age at 
onset 
SNCA duplication in 
AD cases 
      
Nishioka et al. 2006 
and 2009 
Japan 
(Juntendo) 
6 487 1.2  48.2 
Ibanez et al. 2004 and 
2009 
France  
and Italy 
4 286 1.4  43.6 
Sironi et al. 2009 Italy 1 144 0.7  41 
Ikeuchi et al. 2008 Japan  
(Niigata) 
1    57 
Uchiyama et al. 2008 Japan  
(Niigata) 
1    60 
Fuchs et al. 2007 Sweden  
(Lister 
complex) 
1    71 
Ahn et al. 2007 Korea 1 906 0.1  40 
Chartier-Harliln et al. 
2004 
France 1 9 11  50.8 
total average  51.5 
SNCA duplication in 
sporadic cases 
      
Nishioka et al. 2009 Japan 
(Juntendo) 
1 487 0.2  31 
Nuytemans et al.2009 Belgium 1 219 0.5  71 
Brueggemann et al. 
2008 
Germany 1 403 0.3  36 
Troiano et al. 2008 France 1 101 1  35 
Ahn et al. 2007 Korea 2 906 0.2  57.5 
total average  46.1 
SNCA triplication   
Sekine et al. 2010 Japan 
(Juntendo)
1  37 
Ibanez et al. 2009 France 1 286 0.3  42 
Fuchs et al. 2007 Sweden 
(Lister 
complex)
1     
Farrer et al. 2004 Swedish-
American
1    31 
Singlton et al. 2003 Iowa 1  33.2 
SNCA homozygote 
duplication 
    
Ikeuchi et al. 2008 Japan 
(Niigata)
1     28 
total average  32.9 
Table 1. The clinical manifestations and prevalence of SNCA duplication and triplication 
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2.4 The Synuclein family in Parkinson disease 
The SNCA gene is located on chromosome 4q21-22 and is associated with susceptibility to 
PD and DLB. Alpha-synclein has two paralogous genes, beta- (SNCB; MIM#602569) and 
gamma-synuclein (SNCG; MIM#602998) with which it shares a highly conserved N-terminal 
domain. SNCB is located on chromosome 5q35, and SNCG is located on chromosome 10q23 
associated with breast and ovarian cancer (Ji et al., 1997, Goedert, 2001). All three synuclein 
genes are highly expressed in brain; thalamus, substantia nigra, caudate nucleus, and 
amygdala (Lavedan, 1998, Lavedan et al., 1998). A phylogenic tree indicates that alpha- and 
beta- synucleins are related more closely to each other than to gamma-synuclein (Lavedan, 
1998). Interestingly, two putative pathogenic mutations in SNCB are reported to cause DLB, 
however no significant co-segregation with disease could be shown and no other studies 
have identified these variants (Ohtake et al., 2004). A murine model with over-expressed 
gamma-synuclein is reported as a PD model with motor deficits (Ninkina et al., 2009). Our 
recent studies on common variation in the synuclein family of genes also suggested 
association for variants in both SNCA and SNCG with diffuse LB disease (Nishioka et al., 
2010). Given these findings, it is postulated that there is a connection between not only 
SNCA, but also SNCB and SNCG and susceptibility to PD, however multiplications of the 
SNCB and SNCG loci have not yet been observed.  
3. Conclusion and future work 
Research focused on copy number variation has made remarkable progress in recent years. 
Genome-wide studies for copy number variants (CNV) indicate 1447 copy number variable 
regions (CNVRs) (Redon et al., 2006). Presumably, many of these CNV polymorphisms 
result in differential expression levels of proteins and dictate the phenotypic presentation at 
the individual level. Interestingly in Alzheimer disease multiplications of the APP gene have 
also been identified in families with autosomal dominantly inherited forms of the disease 
(Cabrejo et al., 2006, Rovelet-Lecrux et al., 2006). Robust and comprehensive studies are now 
warranted for CNV across the genome and may not only help develop new treatments for 
PD but perhaps several other neurodegenerative diseases.  
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